Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Gilead sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Florida's Agency for Health Care Administration (AHCA) said it plans to make "kick payments" to Medicaid plans to help cover the cost of …

    Published on 6/16/2014
  • Sequenom sales and marketing update

    Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Business: Diagnostic Sequenom said an undisclosed U.S. health insurance company will cover the company's MaterniT21 Plus LDT, which detects trisomies along with fetal sex …

    Published on 6/16/2014
  • Alexion sales and marketing update

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Business: Neurology Alexion recalled nine additional lots of Orphan drug Soliris eculizumab distributed in the U.S. due to the presence of visible particles. …

    Published on 6/9/2014
  • CSL sales and marketing update

    CSL Ltd. (ASX:CSL), Melbourne, Australia Business: Hematology CSL launched a co-pay relief program to offer eligible U.S. patients up to $4,000 per year to be applied to co-payments, deductibles and coinsurance for …

    Published on 6/9/2014
  • Daiichi Sankyo sales and marketing update

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cardiovascular Daiichi launched Efient prasugrel in Japan to treat patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI). …

    Published on 6/9/2014
  • Genalice B.V. sales and marketing update

    Genalice B.V., Harderwijk, the Netherlands Business: Bioinformatics Genalice launched an upgraded version of its DNA data processing software Genalice Map. The company said the software is now able to process the DNA …

    Published on 6/9/2014
  • Merck KGaA sales and marketing update

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Autoimmune Merck's Merck Serono S.A. unit launched in the EU an updated version of its RebiSmart electronic injection device for self-administration of Rebif …

    Published on 6/9/2014
  • Mission Pharmacal, Retrophin Inc. sales and marketing update

    Mission Pharmacal Co., San Antonio, Texas Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Business: Renal Mission granted Retrophin exclusive rights to commercialize Thiola tiopronin in the U.S., where the product is …

    Published on 6/9/2014
  • Ono Pharmaceutical, AstraZeneca sales and marketing update

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Endocrine/Metabolic Ono launched 5 and 10 mg Forxiga dapagliflozin to treat Type II diabetes in Japan. …

    Published on 6/9/2014
  • Pathway Genomics Corp. sales and marketing update

    Pathway Genomics Corp., San Diego, Calif. Business: Diagnostic Pathway Genomics launched its BRCATrue gene test worldwide along with the One for One program, through which it has committed to donate up to $10 million in…

    Published on 6/9/2014
  • Supernus, United Therapeutics sales and marketing update

    Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), Rockville, Md. United Therapeutics Corp. (NASDAQ:UTHR), Silver Spring, Md. Business: Cardiovascular United Therapeutics launched Orenitram treprostinil ER in the U.S. to …

    Published on 6/9/2014
  • Astellas sales and marketing update

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer Astellas launched Xtandi enzalutamide in Japan to treat castration-resistant prostate cancer (CRPC). Japan's National Health Insurance (NHI) price for the…

    Published on 6/2/2014
  • Veracyte sales and marketing update

    Veracyte Inc. (NASDAQ:VCYT), South San Francisco, Calif. Business: Diagnostic Veracyte launched Afirma Malignancy Classifiers in the U.S. to provide preoperative information to help guide surgical strategy in patients …

    Published on 6/2/2014
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Neurology Eisai launched Fycompa perampanel in France and the Netherlands as an adjunct treatment for partial onset seizures, with or without secondarily generalized …

    Published on 5/26/2014
  • Agilent sales and marketing update

    Agilent Technologies Inc. (NYSE:A), Santa Clara, Calif. Business: Diagnostic Agilent's Dako A/S subsidiary launched Anti-CK 8/18 and Anti-TdT for cancer diagnosis. Anti-CK 8/18 is a rabbit mAb against cytokeratin 8 (CK8…

    Published on 5/19/2014
  • Curetis, Heraeus Medical sales and marketing update

    Curetis AG, Holzgerlingen, Germany Heraeus Medical GmbH, Wehrheim, Germany Business: Diagnostic Curetis launched the Unyvero i60 Implant and Tissue Infection cartridge in Europe to detect pathogens and antibiotic …

    Published on 5/19/2014
  • Dara BioSciences sales and marketing update

    Dara Biosciences Inc. (NASDAQ:DARA), Raleigh, N.C. Business: Cancer, Other Dara launched its "No Coupon, No Co-pay, No Hassles" retail patient saving program for Gelclair povidone for oral mucositis and Soltamox …

    Published on 5/19/2014
  • Ferrer, Medivir sales and marketing update

    Grupo Ferrer Internacional S.A., Barcelona, Spain Medivir AB (SSE:MVIR B), Huddinge, Sweden Business: Neurology Medivir launched Adasuve loxapine in Sweden, Norway, Finland and Denmark to treat mild to moderate …

    Published on 5/19/2014
  • Genfa Medica, MediWound sales and marketing update

    Genfa Medica S.A., Geneva, Switzerland MediWound Ltd. (NASDAQ:MDWD), Yavne, Israel Business: Dermatology MediWound granted Genfa exclusive rights to market and distribute NexoBrid in Russia to treat severe burns. …

    Published on 5/19/2014
  • Ipsen sales and marketing update

    Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Business: Endocrine/Metabolic Ipsen said it will begin resupplying Increlex mecasermin in the U.S. on June 2. The company said it will release one …

    Published on 5/19/2014
  • MDxHealth, American Pathology Partners sales and marketing update

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium American Pathology Partners, Brentwood, Tenn. Business: Diagnostic MDxHealth granted American Pathology Partners non-exclusive co-promotion rights in the U.S. to MDxHealth'…

    Published on 5/19/2014
  • Menarini, Vivus sales and marketing update

    Menarini Group, Florence, Italy Vivus Inc. (NASDAQ:VVUS), Mountain View, Calif. Business: Genitourinary In its 1Q14 earnings, Vivus disclosed that Menarini launched Spedra avanafil for erectile dysfunction in France, …

    Published on 5/19/2014
  • MolecularHealth sales and marketing update

    MolecularHealth Inc., The Woodlands, Texas Business: Bioinformatics, Pharmacogenetics In April, MolecularHealth launched TreatmentMAP in Europe and the U.S as a cancer treatment decision support tool. The tool is …

    Published on 5/19/2014
  • Akorn, Santen sales and marketing update

    Akorn Inc. (NASDAQ:AKRX), Lake Forest, Ill. Santen Pharmaceutical Co. Ltd. (Tokyo:4536), Osaka, Japan Business: Ophthalmic Akorn acquired from Santen the NDA and all rights to Betimol timolol solution. Betimol is …

    Published on 1/20/2014
  • Alliance Pharma, Bayer sales and marketing update

    Alliance Pharma plc (LSE:APH), Chippenham, U.K. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Diagnostic, Endocrine/Metabolic Alliance Pharma's Alliance Pharmaceuticals Ltd. subsidiary acquired from Bayer rights …

    Published on 1/20/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993